But agtech investor focus on animal technologies has historically lagged crop technologies as a “less sexy” part of the ecosystem – approximately $4 billion of venture investment vs $18 billion in the last five years, according to AgFunder estimates. Animal-based pharmaceutical firm Ashish Life Sciences (ALS) has raised approximately $4 billion in funding. The investment was led by the Dutch venture arm of Eight Roads, with support from ALS . Anterra Capital will use the funding to scale its business in its existing markets and accelerate its plans to expand into Europe , Australia and Australia . The company produces a variety of products for bees and dairy, poultry and equine animals, including antiparasitics, ectoparasiticides and antibiotics.
Animal-based pharmaceutical firm Ashish Life Sciences (ALS) has raised approximately $4 billion in funding. The investment was led by the Dutch venture arm of Eight Roads, with support from ALS . Anterra Capital will use the funding to scale its business in its existing markets and accelerate its plans to expand into Europe , Australia and Australia . The company produces a variety of products for bees and dairy, poultry and equine animals, including antiparasitics, ectoparasiticides and antibiotics.